Eisai remains deeply committed to a patient-centered approach in Alzheimer's care and ensuring LEQEMBI (R) is available to those eligible and living with early AD in Canada. We will continue to pursue ...

Wolfe Research Auto, Auto Tech and Semiconductor Conference 2026 February 11, 2026 8:50 AM ESTCompany ParticipantsMark Murphy ...

Viehbacher, “Biogen”) announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of “LEQEMBI ® ” (brand name in China: “??? ® ”, ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts ...

Most portfolios are now heavily concentrated in the Mag 7 stocks. For this reason, it is important to pay attention to early money flows in the Mag 7 stocks on a daily basis. Consider continuing to ...

BACKGROUND: The disruption of the blood–brain barrier (BBB) is a central pathogenic event in many central nervous system disorders. However, the mechanisms regulating BBB function remain incompletely ...

By Dr. Priyom Bose, Ph.D. A new study uncovers interferon gamma as both a powerful blood-based signal of Alzheimer’s disease ( AD ) and a potential mechanistic bridge between genetic risk and damaging ...

Background Coronary microvascular dysfunction (CMD) is associated with a poor prognosis but is difficult to diagnose non-invasively. In a recent paper, ST-segment depression on exercise-ECG was found ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced ...

Americans seem to carry bottled water everywhere they go these days. In fact, it has become the second most popular drink (behind soft drinks). But water lovers got a jolt recently when we heard that ...

President Donald Trump’s approval rating decreased one point from last week in the latest poll, as persistent economic concerns and declining confidence in his immigration policies weigh on Americans’ ...